Healthcare Sales & Marketing Network News: kinase

Searching News Database: kinase

Your search returned too many results! The most recent 500 items are shown below:

HSMN NewsFeed - 23 Apr 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Biopharmaceuticals Licensing

HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2026
Think Bioscience Raises $55M in Oversubscribed Series A
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 4 Dec 2025
SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 30 Oct 2025
Brenig Therapeutics Names Megan McGill as Chief Executive Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 2 Sep 2025
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Jun 2025
Sanofi to Acquire Blueprint Medicines, Expanding Portfolio in Rare Immunological Disease and Adding Early-stage Pipeline in Immunology
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 21 Apr 2025
FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Mar 2025
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Feb 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Feb 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate (ADC) Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 31 Jan 2024
Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women
Diagnostics Product Launch

HSMN NewsFeed - 26 Apr 2023
Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Apr 2023
Geneos Therapeutics Secures $5 Million in Series A3 Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Feb 2023
KeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 18 Oct 2022
Dr. Brett King Joins BiologicsMD as Senior Scientific Advisor and Member of the Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Sep 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Aug 2022
Sironax Announces Closing of $200 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 20 Jul 2022
Nuvalent Announces Leadership Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 May 2022
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 May 2022
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Apr 2022
FDA approves Novartis Vijoice(R) (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Mar 2022
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 28 Jan 2022
Blueprint Medicines' AYVAKYT(R) (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Biopharmaceuticals Neurology Venture Capital Personnel

HSMN NewsFeed - 8 Dec 2021
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Nov 2021
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 29 Nov 2021
HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Nov 2021
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2021
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Oct 2021
Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Sep 2021
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Sep 2021
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals

HSMN NewsFeed - 10 Aug 2021
LQT Therapeutics Announces Closing of US$19M Series A Financing to Advance Lead Compound Through Phase 1 while Advancing Portfolio Assets
Biopharmaceuticals Cardiology Venture Capital

HSMN NewsFeed - 3 Aug 2021
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Biopharmaceuticals

HSMN NewsFeed - 3 Aug 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jul 2021
SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Biopharmaceutical Personnel

HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 May 2021
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Apr 2021
HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Mar 2021
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
Diagnostics Oncology FDA

HSMN NewsFeed - 18 Feb 2021
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Biopharmaceuticals Licensing

HSMN NewsFeed - 17 Feb 2021
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jan 2021
Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 Dec 2020
Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea(R) (Paclitaxel Micellar) in Europe
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 21 Dec 2020
Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Dec 2020
Neuron23(TM) Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Nov 2020
Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Nov 2020
Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Nov 2020
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK(R) (Ripretinib) in a Multi-Regional Agreement
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 29 Oct 2020
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 26 Oct 2020
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Sep 2020
Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Sep 2020
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Sep 2020
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Jun 2020
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Diagnostics Oncology Mergers & Acquisitions

HSMN NewsFeed - 16 Jun 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 May 2020
HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 May 2020
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions
Diagnostics Oncology FDA

HSMN NewsFeed - 19 May 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
Diagnostics Oncology FDA

HSMN NewsFeed - 15 May 2020
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 May 2020
Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 28 Apr 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Apr 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jan 2020
PANTHERx(R) Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT(TM) (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 13 Jan 2020
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Jan 2020
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
Biopharmaceuticals Oncology Drug Delivery Licensing

HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2019
Black Diamond Therapeutics Closes $85 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 15 Nov 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Nov 2019
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Nov 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory

HSMN NewsFeed - 25 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Sep 2019
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Diagnostics Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 23 Aug 2019
HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2019
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
Diagnostics Oncology

HSMN NewsFeed - 16 May 2019
Pulmatrix Announces Leadership Change
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Apr 2019
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 2 Apr 2019
Petra Pharma Strengthens Management Team with Recent Leadership Appointments
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Apr 2019
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Mar 2019
Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
Biopharmaceuticals Dermatology Licensing

HSMN NewsFeed - 15 Feb 2019
Lilly Completes Acquisition of Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Biopharmaceuticals Licensing

HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 3 Jan 2019
Tragara Pharmaceuticals Appoints Scott Megaffin as Chief Executive Officer and Changes Name to Adastra Pharmaceuticals
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Nov 2018
Cumberland Pharmaceuticals To Acquire VIBATIV(R)
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory

HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 4 Sep 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
Diagnostics Oncology Product Launch

HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Aug 2018
Roche receives FDA approval for cobas EGFR Mutation Test v2 as companion diagnostic with IRESSA (gefitinib) in first-line treatment of patients with non-small cell lung cancer (NSCLC)
Diagnostics Oncology FDA

HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Aug 2018
Actavalon Announces Appointments of Dr. John Hood to Its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Aug 2018
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jul 2018
HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Jul 2018
Ascentage Pharma Raises $150 Million in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2018
Alpha Biopharma Announces Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jun 2018
BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2018
IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 31 May 2018
Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 May 2018
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 May 2018
Apexigen Expands Leadership Team With Appointment Of Frances Rena Bahjat, Ph.D. Vice President, Discovery Research
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 May 2018
EIP Pharma Secures $20.5 Million in Series B Financing
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 14 May 2018
Lilly to Acquire AurKa Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Apr 2018
Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals

HSMN NewsFeed - 11 Apr 2018
Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
Biopharmaceuticals Oncology Drug Delivery Personnel

HSMN NewsFeed - 26 Mar 2018
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Mar 2018
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Biopharmaceuticals Oncology Urology FDA

HSMN NewsFeed - 9 Mar 2018
Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Feb 2018
Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jan 2018
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 29 Jan 2018
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Dec 2017
Rigel Announces Departure of Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Nov 2017
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 1 Nov 2017
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Oct 2017
SutroVax Appoints Veteran Vaccine Experts to Executive Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Sep 2017
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Sep 2017
Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc
Biopharmaceuticals Licensing

HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Aug 2017
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Aug 2017
Macrophage Pharma Limited Extends Series A Round to Include New Investor Merck Ventures
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Aug 2017
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 20 Jul 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals

HSMN NewsFeed - 17 Jul 2017
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Jul 2017
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jun 2017
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Rigel's New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2017
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Diagnostics Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 May 2017
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 May 2017
NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Apr 2017
Invivoscribe(R) Receives FDA Approval for the LeukoStrat(R) CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt(R) and is the First Companion Diagnostic for AML
Diagnostics Personalized Medicine Oncology FDA

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Apr 2017
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Biopharmaceuticals

HSMN NewsFeed - 4 Apr 2017
Relay Therapeutics Appoints Pharmaceutical Leader Sanjiv K. Patel, M.D. to President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Mar 2017
Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Mar 2017
Athenex Inc. announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Feb 2017
Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jan 2017
Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Dec 2016
Celldex Therapeutics Announces Appointment to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Dec 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Nov 2016
Neurotrope Issues Statement On Eli Lilly's Solanezumab
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Nov 2016
Marina Biotech Announces Merger with IthenaPharma
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 15 Nov 2016
Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Nov 2016
IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 31 Oct 2016
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Oct 2016
Efficacy of Ofev(R) (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
Biopharmaceuticals

HSMN NewsFeed - 13 Oct 2016
Ocular Therapeutix(TM) and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Sep 2016
Dr. Daniel Alkon Appointed President of Neurotrope, Inc.
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Sep 2016
Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Aug 2016
Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Aug 2016
Neurotrope Announces Changes to the Board of Directors and Management
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch

HSMN NewsFeed - 3 Aug 2016
Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation as First-Line Treatment for HR+/HER2- Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 21 Jun 2016
Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Biopharmaceuticals

HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
Biopharmaceuticals Distribution

HSMN NewsFeed - 2 Jun 2016
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
Biopharmaceuticals Oncology Licensing Acquisitions

HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 May 2016
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
Biopharmaceuticals

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Apr 2016
BioMmune Appoints Dr. Patrick Gray as New Chief Executive Officer and President
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Apr 2016
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 1 Mar 2016
FLAG Therapeutics Announces the Granting of Orphan Drug Designation to FLAG-003 in both the US and EU for the Treatment of Glioma
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 19 Feb 2016
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 3 Feb 2016
LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Feb 2016
MISSION Therapeutics Raises £60 million to Progress Development of Novel DUB Inhibitors from Innovative Drug Platform
Biopharmaceuticals Oncology Neurology Venture Capital

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jan 2016
iCo Strategic Reorganization
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jan 2016
C4 Therapeutics Launches with $73 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 22 Dec 2015
eFFECTOR Therapeutics Raises $40 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Dec 2015
Navitor Pharmaceuticals Announces $33 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Dec 2015
eFFECTOR Therapeutics Appoints Alana McNulty Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2015
Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Dec 2015
Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Dec 2015
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2015
Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Oct 2015
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Oct 2015
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Biopharmaceuticals Oncology Dermatology

HSMN NewsFeed - 30 Sep 2015
Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2015
CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 Sep 2015
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 25 Aug 2015
Panther Biotechnology, Inc. Announces $1.215 Million Financing With Chicago Venture Partners
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Aug 2015
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jul 2015
Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 May 2015
Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in Solid and Liquid Patient Samples Using Multiplexed ICE COLD-PCR(TM)
Diagnostics Oncology Product Launch

HSMN NewsFeed - 8 May 2015
Armetheon, Inc. Announces Appointment of Andrew C. Lam as Vice President of Product Development
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 14 Apr 2015
Infinity Augments Executive Leadership Team, Appointing Chief Commercial Officer and General Counsel
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Oncology Personnel

HSMN NewsFeed - 18 Mar 2015
U.S. Food and Drug Administration Approves Cholbam for the Treatment of Rare Bile Acid Synthesis Disorders and Grants Rare Pediatric Disease Priority Review Voucher
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Mar 2015
CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Feb 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
Diagnostics Personnel

HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Nov 2014
Blueprint Medicines Secures $50 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Aug 2014
Caris Molecular Intelligence(TM) Identifies Key Biomarkers of Clinical Benefit and Resistance to Chemotherapy through Multi-Technology Tumor Profiling
Diagnostics Oncology

HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Jun 2014
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 19 Jun 2014
Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing for Novel Drug Discovery Targeting Cellular Nutrient Signaling to Treat Chronic Diseases and Rare Disorders
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Jun 2014
EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals
Biopharmaceuticals

HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 May 2014
Retrophin Names Stephen Aselage President and Chief Operations Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 May 2014
FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Apr 2014
Kala Pharmaceuticals Announces $22.5 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 22 Apr 2014
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 8 Apr 2014
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Apr 2014
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Mar 2014
Kolltan Pharmaceuticals Obtains $60 Million in Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Mar 2014
William R. Ringo Joins Mirati Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2014
Ignyta Appoints Sara Zaknoen, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Feb 2014
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 13 Feb 2014
Principia Biopharma Expands Executive Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2014
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 6 Jan 2014
Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 18 Dec 2013
Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2013
Retrophin Announces Agreement to Acquire Kyalin Biosciences
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 14 Nov 2013
Jeffrey Paley, MD, Joins Retrophin Inc.’s Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Oct 2013
G1 Therapeutics Raises $12.5M Series A Financing Led by MedImmune Ventures
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 3 Oct 2013
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Sep 2013
Cornelius E. Golding Joins Retrophin, Inc.’s Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Sep 2013
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Sep 2013
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Sep 2013
Amakem Appoints Jean Marie Stassen as Vice President, Research and Development
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Aug 2013
Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jul 2013
Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jul 2013
Aerie Pharmaceuticals Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 May 2013
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Apr 2013
Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Apr 2013
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Apr 2013
Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Apr 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Apr 2013
Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory Board
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 25 Mar 2013
XELJANZ(R) (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Mar 2013
Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer
Regenerative Medicine Cardiology Personnel

HSMN NewsFeed - 19 Feb 2013
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Feb 2013
Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma
Biopharmaceuticals Oncology Regulatory FDA

HSMN NewsFeed - 13 Feb 2013
Kolltan Pharmaceuticals Expands Senior Management Team, Appoints Jane Henderson as Senior Vice President & Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jan 2013
Verastem Promotes Chief Operating Officer Robert Forrester to President
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Jan 2013
Tim Mayleben Named President And CEO Of Esperion Therapeutics
Biopharmaceuticlas Personnel

HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2012
Flexion Therapeutics Secures $20 Million in Series B Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 8 Nov 2012
Auspex Pharmaceuticals Closes $25 Million Series D Financing
Biopharmaceuticals Neurology Venture Capital Personnel

HSMN NewsFeed - 7 Nov 2012
U.S. Food and Drug Administration Approves Pfizer’s XELJANZ(R) (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Oct 2012
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 22 Oct 2012
Kinex Pharmaceuticals Closes First Tranche of Current Round Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Oct 2012
Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 18 Oct 2012
Omeros Adds Vice Presidents of Regulatory and Clinical to Management Team
Biopharmaceuticals Neurology Surgery Personnel

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2012
Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Sep 2012
Confluence Announces $4 Million in Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Jul 2012
Infinity Announces New Addition to Senior Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jul 2012
NovImmune Strengthens Board and Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Jul 2012
Jeff Cooper Joins KaloBios as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jun 2012
Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Myotonic Dystrophy
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2012
Oncothyreon Announces Promotion of Scott Peterson, Ph.D., to Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Jun 2012
AstraZeneca Completes Acquisition of Ardea Biosciences
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jun 2012
Debiopharm and Ascepion Pharmaceuticals, Inc. Announce Exclusive License Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jun 2012
ORENCIA(R) (abatacept) Demonstrates Comparable Efficacy to Humira(R) (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2012
Phase 3 Data on Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Phase III Data on Bayer's Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 May 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Apr 2012
Kolltan Pharmaceuticals Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Apr 2012
AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Mar 2012
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational Programme and Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD
Biopharmaceuticals

HSMN NewsFeed - 8 Mar 2012
Celgene Completes Acquisition of Avila Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Mar 2012
Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion; Acquisition Includes a World-Leading Pipeline Targeting Cancer Stem Cells
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 29 Feb 2012
Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases
Biopharmaceuticals

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jan 2012
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jan 2012
Celgene to Acquire Avila Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 9 Jan 2012
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair(TM)* in COPD and Asthma
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Nov 2011
H3 Biomedicine Names Markus Warmuth Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Oct 2011
Phase III Trial of Bayer's Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2011
Creabilis Raises 15M ($20M) in Series B Fundraising Round
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals

HSMN NewsFeed - 27 Aug 2011
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
Diagnostics Personalized Medicine Oncology FDA

HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Aug 2011
Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Aug 2011
Creabilis Expands Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA

HSMN NewsFeed - 4 Aug 2011
Creabilis Appoints Dr David Roblin as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jul 2011
Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jun 2011
Agennix Hires Jill Porter as Senior Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jun 2011
TESARO Announces $101 Million Series B Financing for Advancement and Expansion of Oncology Product Portfolio
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 25 May 2011
NanoBio(R) Appoints Peter Ulrich to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 May 2011
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Apr 2011
Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Apr 2011
Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2011
Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments
Personalized Medicine Oncology Venture Capital

HSMN NewsFeed - 11 Apr 2011
Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Apr 2011
Daiichi Sankyo Completes Plexxikon Acquisition
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 22 Mar 2011
TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Mar 2011
Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Dec 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Dec 2010
Accelerator Corporation Finances Eleventh Startup with Acylin Therapeutics, Inc.
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Oct 2010
Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide
Biopharmaceuticals

HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Sep 2010
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jul 2010
Karen Lackey Named Vice President and Head of Medicinal Chemistry at Roche
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Jun 2010
Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 21 Jun 2010
New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan
Biopharmaceuticals Cardiology

HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2010
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Apr 2010
Lycera Achieves $11 Million Second Tranche in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Apr 2010
Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Apr 2010
Altheos Completes $20 Million Series A Financing to Develop Next-Generation Glaucoma Treatment
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Mar 2010
Portola Pharmaceuticals Announces Senior Management and Board Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Mar 2010
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Mar 2010
Stephen Hitchcock to Head Drug Discovery at Envoy Therapeutics
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Feb 2010
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Feb 2010
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)
Biopharmaceuticals Licensing

HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jan 2010
Ligand Completes Acquisition of Metabasis
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2010
Kolltan Pharmaceuticals Closes $10 Million Series B Related Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Jan 2010
AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
Personalized Medicine Diagnostics Biopharmaceuticals

HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Dec 2009
Oxford BioTherapeutics Appoints Michael Moore as Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 18 Nov 2009
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
Diagnostics Oncology Distribution

HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Nov 2009
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Oct 2009
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 9 Oct 2009
Lycera Appoints Key Executives to Drug Development Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2009
Portola Pharmaceuticals Announces Promotions of Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Sep 2009
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 314

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 314 additional stories matching:
kinase
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!